CN1131068C - Composite lysostaphin enzyme spray for oral cavity and its preparing process - Google Patents
Composite lysostaphin enzyme spray for oral cavity and its preparing process Download PDFInfo
- Publication number
- CN1131068C CN1131068C CN 00116396 CN00116396A CN1131068C CN 1131068 C CN1131068 C CN 1131068C CN 00116396 CN00116396 CN 00116396 CN 00116396 A CN00116396 A CN 00116396A CN 1131068 C CN1131068 C CN 1131068C
- Authority
- CN
- China
- Prior art keywords
- spray
- lysozyme
- oral cavity
- oral
- staphylococcus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000007921 spray Substances 0.000 title claims abstract description 18
- 108090000988 Lysostaphin Proteins 0.000 title claims abstract description 13
- 239000002131 composite material Substances 0.000 title claims abstract description 10
- 210000000214 mouth Anatomy 0.000 title claims description 32
- 238000000034 method Methods 0.000 title claims description 10
- 230000008569 process Effects 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 108010014251 Muramidase Proteins 0.000 claims description 25
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 25
- 229960000274 lysozyme Drugs 0.000 claims description 25
- 239000004325 lysozyme Substances 0.000 claims description 25
- 235000010335 lysozyme Nutrition 0.000 claims description 25
- 241000191940 Staphylococcus Species 0.000 claims description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 16
- 230000001954 sterilising effect Effects 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 9
- 239000000686 essence Substances 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 108010001478 Bacitracin Proteins 0.000 claims description 8
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 8
- 235000011009 potassium phosphates Nutrition 0.000 claims description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 7
- 239000000600 sorbitol Substances 0.000 claims description 7
- 229960003071 bacitracin Drugs 0.000 claims description 6
- 229930184125 bacitracin Natural products 0.000 claims description 6
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 229910000831 Steel Inorganic materials 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 239000010959 steel Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 102000016943 Muramidase Human genes 0.000 claims 4
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 14
- 239000000668 oral spray Substances 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 229940041678 oral spray Drugs 0.000 abstract description 11
- 206010059866 Drug resistance Diseases 0.000 abstract description 6
- 239000004615 ingredient Substances 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000003381 stabilizer Substances 0.000 abstract description 2
- 238000013329 compounding Methods 0.000 abstract 1
- 239000002075 main ingredient Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 30
- 239000000523 sample Substances 0.000 description 27
- 241000191967 Staphylococcus aureus Species 0.000 description 25
- 241000894006 Bacteria Species 0.000 description 22
- 102100033468 Lysozyme C Human genes 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 19
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- 241000194017 Streptococcus Species 0.000 description 11
- 238000010171 animal model Methods 0.000 description 11
- 230000002949 hemolytic effect Effects 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 9
- 238000004140 cleaning Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000009471 action Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000222122 Candida albicans Species 0.000 description 7
- 208000025157 Oral disease Diseases 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 208000030194 mouth disease Diseases 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 229920000742 Cotton Polymers 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 229940095731 candida albicans Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 241001478240 Coccus Species 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000000795 conjunctiva Anatomy 0.000 description 5
- 239000013068 control sample Substances 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 5
- 231100000021 irritant Toxicity 0.000 description 5
- 239000002085 irritant Substances 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 231100000017 mucous membrane irritation Toxicity 0.000 description 5
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 4
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108010013639 Peptidoglycan Proteins 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000000249 desinfective effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000001408 fungistatic effect Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 241000192125 Firmicutes Species 0.000 description 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 3
- 208000009019 Pericoronitis Diseases 0.000 description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012459 cleaning agent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 208000007565 gingivitis Diseases 0.000 description 3
- 238000002663 nebulization Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 206010006326 Breath odour Diseases 0.000 description 2
- 108010065152 Coagulase Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000032139 Halitosis Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008261 resistance mechanism Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000012289 standard assay Methods 0.000 description 2
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
- 229930182847 D-glutamic acid Natural products 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710132682 Lysozyme 1 Proteins 0.000 description 1
- 101710132699 Lysozyme 2 Proteins 0.000 description 1
- 101710132698 Lysozyme 3 Proteins 0.000 description 1
- 102100026848 Lysozyme-like protein 2 Human genes 0.000 description 1
- 241001093152 Mangifera Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241001537924 Tetracoccus <angiosperm> Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 206010030983 oral lichen planus Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940072132 quinolone antibacterials Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides an oral composite lysostaphin spray and a preparation method thereof. The spray of the present invention is prepared by compounding lysostaphin as a main ingredient with a stabilizing agent, a synergist and other effective biological ingredients. The oral composite lysostaphin spray has the advantages of strong bactericidal activity, high stability and incapability of generating drug resistance, and the oral composite lysostaphin spray which is a biotype oral spray has no toxic or side effect.
Description
The present invention relates to biological preparation, be specifically related to a kind of composite lysostaphin enzyme spray for oral cavity and preparation method.
The oral cavity is the important barrier of people's human body with extraneous contact, is an ingredient of respiratory system, digestive system, also is the part that is vulnerable to encroach on most simultaneously, comprises the infringement of air pollution, antibacterial etc.Along with the air-polluting aggravation, the deterioration of environment, the incidence rate of oral disease has improved greatly.
There are numerous pathogenic bacterium in the oral cavity, wherein account for comprising of main ratio: antibacterials such as staphylococcus, Hemolytic streptococcus, Candida albicans, anaerobe.They are the root of oral disease still not, but also influence the normal absorption of nutrition even can cause that such as respiratory tract therefore the disease of organs such as gastrointestinal prevents and kill oral cavity pathogen, to safeguarding human oral cavity health, the sickness rate that reduces other organ is very crucial.
For a long time, the oral cavity treatment of diseases is adopted chemistry, antibiotics always, although played a role at that time, along with the use repeatedly of these medicines, brought a series of adverse effect---produced many drug-fast strains, brought toxic and side effects to human body.Endurance strain shared ratio in pathogenic bacterium has the gesture of rising year by year now.
Antibiotic is to work in the metabolic process of bacterial growth, can only play the purpose of bacteria growing inhibiting, and it all can not be killed, and the antibacterial that a part is survived will have the antibiotic resistance of this kind.
Used cleaning agent for mouth cavity mainly contains four kinds of compositions: ethanol, wetting agent, surfactant and essence.In order to prevent halitosis, most sprays are allocated antibacterial into, and it is mainly metronidazole, hibitane and some Chinese medicine such as SHUANGHUANLIAN etc.Can reach fungistatic effect preferably though add antibacterial, because the very easy generation fastbacteria of chemical drugs also has stimulation to oral mucosa, Cuo is very big to gastric irritation as first nitre, is difficult for being accepted by the people.
In the oral cavity infection treatment of diseases, present stage is still based on chemistry and antibiotics.For example, old people oral cavity candidiasis is mainly used nystatin and cydiodine, acute pericoronitis first nitre Cuo, and oral lichen planus waits with first nitre Cuo and tetracycline and treats, and these medicines are toxic side effect all, but also the bacterial strain that can develop immunity to drugs.Also do not have a kind of real effectively full biological preparation at present, can effectively sterilize and without any side effects, but also be difficult for developing immunity to drugs.
The objective of the invention is to overcome above-mentioned shortcoming, develop a kind of having no side effect, be difficult for producing drug resistance, efficient, broad-spectrum bactericidal biotype cleaning agent for mouth cavity.
The invention provides a kind of composite lysostaphin enzyme spray for oral cavity, this spray is formed (percentage by weight) by following composition:
Main component: 1. staphylococcus lysozyme (lysostaphin) 1-3%
2. lysozyme (lysozyme) 10-20%
Adjuvant: 3. sorbitol (sorbic alcohol) 6-7%
4. potassium phosphate (potassium phosphate) 7-10%
5. sodium chloride (sodium chloride) 0.5-1%
6. essence (essence) 0.1%
7. bacitracin (bacitracin) 2-3%
8. distilled water (distilled water) 60-70%
The sterilizing mechanisms of oral spray of the present invention is as follows:
Staphylococcus lysozyme is a kind of bacteriolysin of gram positive bacteria.Form the aminoacid of the tetrapeptide side chain of such gram positive bacteria (for example staphylococcus aureus) whole cell peptidoglycan, be followed successively by the L-alanine, D-glutamic acid, L-lysine, D-alanine; And the first L-alanine links to each other with 3-O-.alpha.-carboxyethyl-D-glucosamine. by an amido link, and the L-lysine that this polysaccharide chains tetrapeptide side chain is the 3rd is attached on the adjacent polysaccharide chains tetrapeptide side chain D-alanine carboxyl by pentapeptide (five glycine) cross-bridge.Intersect in length and breadth thus, about connect and constitute very tough and tensile 3 D stereo loose structure, and aggregate into thicker Peptidoglycan layer.Staphylococcus lysozyme can cut off the Gly-Gly key in the Peptidoglycan, and another kind of enzyme can cut off key between-acetylmuramic acid and the N-acetylglucosamine in the molten Portugal coccus compound enzyme, thereby make bactericidal activity stronger, reach the purpose of dissolving and killing bacteria, and can avoid the generation of bacterial drug resistance.
Because the sterilization mechanism of staphylococcus lysozyme uniqueness makes it be different from general antibiotic.Except that producing beta-lactamase, also there is other resistance mechanism in the resistance mechanism complexity of drug resistance staphylococcus aureus.To antibacterials commonly used, more Resistant strain is also arranged according to clinical observation MRSA as penicillin, benzylpencilline one, third generation cephalosporin class antibiotic and some Novel Quinolone antibacterials.From above-mentioned situation; though new antibiotic is arranged constantly to be developed and comes into operation; produce but just have new Resistant strain in very short time, this is because most of antibiotics bacteria growing inhibiting impels the R-plasmid of Production by Bacteria tissue regeneration promoting or the effect that new enzyme stops antibiotics.The mechanism of action of staphylococcus lysozyme is different from general antibiotic, and antibiotic effect only is a bacteria growing inhibiting, and this enzyme then is a cracking antibacterial killing bacteria, and the staphylococcus aureus of methicillin-resistance (MRSA) is had stronger sterilizing ability equally.
Staphylococcus lysozyme can produce bacteriolysis by hydrolysis gram-positive bacterium whole cell peptidoglycan, thereby thorough killing bacteria has been avoided the generation of bacterial drug resistance.The antibacterial of strain more than 400 that units such as the Huashan, Shanghai City hospital institute of Antibiotics, The 2nd Army Medical College Changhai hospital laboratory, Shanghai City Sixth People's Hospital clinical laboratory, Shanghai City the 9th the People's Hospital clinical laboratory once collected clinical each section has carried out the sterilization experiment that presses down of staphylococcus lysozyme.Experimental result shows: staphylococcus lysozyme is to gram positive bacteria, as common clinically staphylococcus aureus, staphylococcus epidermidis, Diplococcus pneumoniae, D group enterococcus, tetracoccus, product monokaryon Listerella, streptococcus and stomach Helicobacter pylori etc. all have tangible inhibitory or killing effect.
Experiment also proves staphylococcus lysozyme to endurance strain, and as feeling most thorny methicillin-resistant staphylococcus aureus on the present clinical medicine, drug resistance Diplococcus pneumoniae, the effect of having a liking for the narrow food sporangium of Fructus Hordei Germinatus more are better than common antibiotics.
Oral spray of the present invention can be efficiently presses down cells such as the staphylococcus aureus that causes pharyngolaryngitis, tonsillitis, oral ulcer, gingivitis, periodontitis, pericoronitis, papillary gingivitis extremely, Hemolytic streptococcus, streptococcus pneumoniae, colibacillus, Candida albicans, fungus, anaerobe, sterilizing rate 99.9%.Have no side effect, non-stimulated to mucosa.
The fungistatic effect of composite lysostaphin enzyme spray for oral cavity of the present invention (FE compound enzyme mouth cleaning solution) and effect are as follows through Shanghai Disease Prevention and Control Centre's testing result: (one) bacteriostasis detects: the sample title: FE compound enzyme mouth cleaning solution quantity: 1 send the verification certificate position: Gaoke Bio-Engineering Co Ltd, Shanghai's inspection technology foundation: with reference to the disposable use hygienic article of GB15979-1995 sanitary standard assay with estimate one, the result:
1, to the bacteriostasis of escherichia coli (8099): different (min) bacteriostasis rates action time of concentration (%) (%)
123 5,100 100 100 100 10,050 99.98 100 100 100 annotate: contrast bacterium number is 5.5 * 10
4Cfu/ml
2, to the bacteriostasis of staphylococcus aureus (ATCC 6538): different (min) bacteriostasis rates action time of concentration (%) (%)
123 5,100 100 100 100 10,050 99.98 100 100 100 annotate: contrast bacterium number is 7.1 * 10
4Cfu/ml
3, to the bacteriostasis of Candida albicans (ATCC 10231): different (min) bacteriostasis rates action time of concentration (%) (%)
123 5,100 99.99 100 100 10,050 99.97 99.99 100 100 annotate: contrast bacterium number is 9.2 * 10
4Cfu/ml
4, to the bacteriostasis of Hemolytic streptococcus (32210): different (min) bacteriostasis rates action time of concentration (%) (%)
123 5,100 100 100 100 10,050 99.99 100 100 100 annotate: contrast bacterium number is 9.5 * 10
4Cfu/ml
5, (bacteriostasis of porphyromonas gingivalis: different (min) bacteriostasis rates action time of concentration (%) (%) to anaerobe
123 5,100 100 100 100 10,050 99.97 100 100 100 annotate: contrast bacterium number is 8.5 * 10
4Cfu/ml
6, field trial:
Select 10 volunteers, lower teeth is embrocated secondary with the disinfecting silk or cotton examination on the oral cavity, this cotton is wiped away put into 10ml 1% peptone PBS, gets 1ml after shaking up and puts into sterilization plate cultivation counting this (background) in contrast.To mouthspray FE compound enzyme mouth cleaning solution 1 minute, wipe away by last method sampling with disinfecting silk or cotton and to cultivate counting during test.In addition product is diluted to 50% concentration 50ml and gargled 1 minute, cultivate counting by preceding method sampling.And do Hemolytic streptococcus, staphylococcus aureus, anaerobic culture.In process of the test, untoward reaction such as dizziness, vomiting, diarrhoea, allergy do not appear in the volunteer.(1) bacteriostasis nebulization bacteriostasis rate (%) the Buccodental bacteria colony count (cfu/ml) of nebulization
92.82 1.4 * 10
5(2) method bacteriostasis method bacteriostasis rate (%) the Buccodental bacteria colony count (cfu/ml) of gargling of gargling
91.47 1.4 * 10
5Annotate: nebulization, even Hemolytic streptococcus, staphylococcus aureus, the anaerobe of not detecting of the method for gargling.
7, bacteriological detection detects index result standard value total number of bacterial colonies (cfu/g)＜10≤20 coliform and must not detect and detect staphylococcus aureus and must not detect and detect Pseudomonas aeruginosa and must not detect and detect hemolytic streptococcus and must not detect and detect fungi and must not detect and detect two, estimate:
This product 50% mass action 1 minute all has stronger bacteriostasis to escherichia coli, staphylococcus aureus, Candida albicans, Hemolytic streptococcus, anaerobe; Through on-the-spot volunteer test, to mouthspray, gargle, bacteriostasis rate is respectively 92.82% and 91.47%.Do not detect Hemolytic streptococcus, staphylococcus aureus, anaerobe after the test.Through Bacteria Detection, meet GB15979-1995.(2) fungistatic effect test sample title: FE compound enzyme mouth cleaning solution quantity: 1 sample labelling: do not have and send the verification certificate position: Gaoke Bio-Engineering Co Ltd, Shanghai's inspection technology foundation: Ministry of Public Health " disinfection technology standard " 1991 assays and evaluation:
Select doubtful upper respiratory tract infection personnel 15 people in certain hotel, at first wipe away in oral cavity and throat portion sampling with disinfecting silk or cotton, after cotton wiped away insert saline tube and take back laboratory.Above-noted persons use FE compound enzyme mouth cleaning solution spraying oral cavity 5 times in one day simultaneously, and the reuse disinfecting silk or cotton is wiped away in oral cavity and throat portion and sampled every other day.Sample advances direct inoculation blood plate behind the laboratory, and transferred species SCDLP liquid, and 37 ℃ increased bacterium 18 hours, inoculation blood plate.The blood plate is cultivated 18 hours observed results for 37 ℃, and suspicious staphylococcus aureus carries out form, biochemistry and coagulase test of blood plasma.Other establishes does not spray medicine and contrasts 6 people, as stated above in the next day sample simultaneously.The test group matched group is sampled staphylococcus aureus recall rate (%) and is sampled before staphylococcus aureus recall rate (%) the number spray medicine behind the spray medicine number 15 46.67 06 50 and annotates: staphylococcus aureus is through form, the mannose ferment test, coagulase test of blood plasma confirms to estimate: certain hotel is from doubtful upper respiratory tract infection crowd, if test group 15 people, matched group 6 people, before the test group spraying FE compound enzyme mouth cleaning solution, the staphylococcus aureus recall rate is 46.67%, after the spraying, the staphylococcus aureus recall rate is 0.Matched group staphylococcus aureus recall rate is 50%, illustrates that this cleaning solution has certain fungistatic effect.(3) bacteriostatic test sample title: FE compound enzyme mouth cleaning solution quantity: 1 send the verification certificate position: Gaoke Bio-Engineering Co Ltd, Shanghai's inspection technology foundation: the disposable use hygienic article of GB 15979-1995 sanitary standard assay and evaluation: stability test:
1) sample is through doing in 54 ℃ of two week to different (min) bacteriostasis rates action time of bacteriostatic test concentration (%) of staphylococcus aureus (%)
25 10 20,100 99.68 99.98 100 10,050 99.43 99.65 99.98 100 annotate: contrast bacterium number is 8.0 * 10
4Cfu/ml
2) sample through 37 ℃ three months, do (%) different (min) bacteriostasis rates action time of bacteriostatic test concentration (%) of staphylococcus aureus
25 10 20,100 96.41 96.78 97.96 98.3250 95.08 96.37 97.61 98.23 annotate: contrast bacterium number is 8.0 * 10
4Cfu/ml
3) estimate
Sample was through 54 ℃ of two week and 37 ℃ three months, and 50% concentration still has by force bacteriostasis to staphylococcus aureus.
The metal detection result of staphylococcus lysozyme oral spray of the present invention is as follows: the sample title: FE compound enzyme mouth cleaning solution quantity: 1 send the verification certificate position: Gaoke Bio-Engineering Co Ltd, Shanghai's inspection technology foundation:
GB/T?5009.12-1996 Gb/T?5009.11-19
GB/T 5009.17-1996 assay and evaluation
Plumbous (mg/L): 0.02
Arsenic (mg/L): do not detect
Hydrargyrum (mg/L): do not detect
The toxicity and the irritant test of staphylococcus lysozyme oral spray of the present invention (FE collutory) are as follows through Shanghai Disease Prevention and Control Centre's testing result:
One, acute toxicity (per os LD
50) test:
Purpose: sample contacts the health hazard that can cause and obtains half lethal dose by a per os, for acute toxicity is classified, classification provides according to (for subchronic test and the definite dosage of other test provide reference).
1, sample character: transparency liquid, water-soluble
2, sample treatment and preparation: sample thief 5000mg adding distil water is to 20ml, for examination.
3, experimental animal: Kunming mouse, body weight 18-22 gram provides the (quality certification number: 02-22-1) by laboratory animal portion of Shanghai Medical Univ
4, experimental technique: by " disinfection technology standard (Ministry of Public Health 1991) " test.
4.1 before the test, laboratory animal fasting 16 hours.
4.2 with the animal random packet, each one group of male and female, 10 every group, weigh, press the 0.4ml/20g body weight, adopt administration by gavage to carry out once giving sample.
4.3 observe in two weeks behind the sample poisoning manifestations of laboratory animal and death condition.
4.4 calculate LD
50And 95% credibility interval.
5, result:
Table male and female chmice acute per os toxicity test is animal sex dosage number of animals death toll LD as a result
50And 95%
(mg/kg) (only) (only) fiducial limit (mg/kg) female mice 5,000 10 0＞5000 male mices 5,000 10 0＞5000
6, conclusion: female mice: LD
50＞5000mg/kg
Male mice: LD
50＞5000mg/kg two, micronucleus test:
1, sample character: transparency liquid, water-soluble
2, the processing of sample and preparation: sample thief 2500,1000,500,250mg adding distil water respectively are made into concentration and are 125,50,25, the solution of 12.5mg/ml to 20ml, for examination.
3, laboratory animal:
3.1 source: laboratory animal portion of the Shanghai Medical Univ (quality certification number: 02-22-1)
3.2 kind and strain: Kunming mouse
3.3 sex: female, male
3.4 body weight: 25-30 gram
4, experimental technique;
4.1 animal is divided into 6 groups at random, and 8 every group, male and female half and half are respectively as four dosage groups of sample and negative control and positive controls.
4.2 adopt administration by gavage 30 hours twice, animal is weighed, and the variable concentrations sample of preparation is pressed the 0.4ml/20g body weight, respectively each treated animal is irritated stomach.
4.3 after for the second time irritating stomach 6 hours, animal was put to death in the cervical vertebra dislocation, got bone marrow of sternum and added the calf serum mixing, routine smear, fixing Giemsa stained preparation.
4.4 microscopy is observed, the microkernel incidence of 1000 polychromatic erythrocytes of every Mus counting, and carry out statistical analysis.
5, result:
Table animal bone marrow polychromatic erythrocyte microkernel incidence dosage sex number of animals is examined the cell number micronucleus cell and is counted micronuclear rates statistics (mg/kg) (only) (individual) (individual) (‰) check
*Male 4 4,000 77 19.2＜0.01 (the endoxan 40mg/kg) female 4 4,000 78 19.5＜0.01 of female 4 4,000 8 2.0 positive controls of male 4 4,000 7 1.8 (the distilled water 20000mg/kg) of 2500 male 4 4,000 6 1.5＞0.052500 female 4 4,000 5 1.2＞0.051000 male 4 4,000 4 1.0＞0.051000 female 4 4,000 5 1.2＞0.05 500 male 4 4,000 6 1.5＞0.05 500 female 4 4,000 7 1.8＞0.05 250 male 4 4,000 5 1.2＞0.05 250 female 4 4,000 6 1.5＞0.05 negative controls
*Compare with negative control group (through X 2 test)
6, conclusion: credit is analysed by statistics, and the result is negative for sample bone marrow polychromatic erythrocyte micronucleus test.Three, mucomembranous irritant test:
1, purpose: pass through eye irritant test: point out when eye in case the harm situation that may occur after contacting this sample.
2, sample character: transparency liquid, water-soluble.
3, sample treatment: sample is directly tested.
4, laboratory animal: rabbit is planted by New Zealand, and 4, body weight 2-3kg, male and female half and half are provided by laboratory animal portion of Shanghai Medical Univ.The quality certification number: 02-52-1
5, experimental technique
5.1 laboratory animal one branch hole eyelid is drawn back gently, 0.1ml (g) is tried thing splashed into (or putting into) conjunctival sac, up and down the catacleisis several seconds, another branch hole compares with normal saline.
5.2 24h washes (zest powerhouse, can be behind eye drip 30s flushing) behind the eye drip.
5.3, the laboratory animal eyes are checked respectively at behind the eye drip 6,24,48 and 72h, 4d, 7d.Carry out the mucous membrane irritation intensity evaluation by disinfection technology standard (Ministry of Public Health 1991).
6, result: the reaction of experimental animal mucous membrane irritation does not see that conjunctiva is not impaired towards blood, edema, cornea, iris.
Table rabbit mucomembranous irritant test number of animals position mucous membrane irritation reaction as a result integration
6h 24h 48h 72h 4d 7d
Sample/control sample/control sample/control sample/control sample/control sample/contrast 1 conjunctiva 000000000000
Iris 000000000000
Cornea 000000000000
Total points 00000000000 02 conjunctivas 000000000000
Iris 000000000000
Cornea 000000000000
Total points 0000000000003 conjunctivas 000000000000
Iris 000000000000
Cornea 000000000000
Total points 00000000000 04 conjunctivas 000000000000
Iris 000000000000
Cornea 000000000000
Total points 000000000000 total marks 000000000000 average SI 000000000000 MMi integrations, 000000000000 indexes (I.A.O.I) 48h stimulate average index (M.I.O.I) 00
The stimulus intensity nonirritant
7, conclusion: this product mucous membrane irritation integral exponential is 0, is 0 behind the mucous membrane irritation average index 48h, belongs to nonirritant.
Another object of the present invention has provided the preparation method of above-mentioned staphylococcus lysozyme oral spray, this method is in sterilizing room, staphylococcus lysozyme (is bought from U.S. Sigma company,), lysozyme, sorbitol, potassium phosphate, sodium chloride, add successively in proportion in the clean glass or rustless steel container, stir gently, fully mixed evenly after, the bacteriostatic peptide bacitracin of ratio shown in adding again, essence and distilled water, abundant mixing, fill is in plastic bottle or metal bottle, warehouse-in, room temperature preservation gets final product.
Molten Portugal of the present invention coccus compound enzyme oral spray is to be main component with the staphylococcus lysozyme, be equipped with stabilizing agent, synergist etc. effectively biotic component be composited, have bigger stability than pure lysostaphin, stronger bactericidal activity.It plays the purpose of killing bacteria by direct cracking bacteria cell wall, can not cause similar antibiotic selection pressure to antibacterial, so can not develop immunity to drugs under its effect.As a kind of protease, it will be decomposed, utilize in the metabolism of human body, so it is absolute harmless to human body.Belong to the novel cleaning agent for mouth cavity of initiative both at home and abroad.
This product is according to the oral hygiene principle, with molten Portugal coccus compound enzyme is main component, be aided with some natural flavorants, make this oral spray not only can effectively treat bacterial oral diseases such as staphylococcus, Hemolytic streptococcus, Candida albicans, anaerobe, can also play the effect of fresh breath.Because this product effective ingredient is a protease, so it is nontoxic to human body, have no side effect, and it can not develop immunity to drugs, so it is still infected the choice drug of the oral disease that causes by antibiotic-resistant bacteria, other medicines are incomparable especially to the therapeutic effect of some oral cavity persistent ailments.
Molten Portugal coccus compound enzyme oral spray detects the fragmentation effect of antibacterials such as main several pathogenic bacterium that cause oral disease such as staphylococcus, Hemolytic streptococcus, Candida albicans, anaerobe through holder Shanghai Disease Prevention and Control Centre, finds that these product have the good sterilization effect.Carried out acute toxicity test, micronucleus test, mucomembranous irritant test, stability experiment simultaneously and proved that its every security performance meets the requirements.Through how tame department of stomatology, Hospital such as Shanghai oral disease control institute, Shanghai Second Emdical University's School of Stomatology, Shanghai City stomatology institutes the treatment of oral diseases such as periodontal disease, stomatocace, pericoronitis, gingivitis is found that molten Portugal coccus compound enzyme oral spray is the medicine and the dental care product of ideal treatment oral cavity inflammatory illness.
Because this oral spray can effectively sterilize, and is easy to use, saves time, and do not need special apparatus, it will be used widely in hospital.In hospital, on the one hand, a large amount of oral cavity patients use clinical the needs, other patients such as tumor patient because handicapped, also to use this spray in order to remove halitosis.On the other hand, a part of anemia of pregnant woman and child also will be its consumers.
Example: the compound method of every manufacturing 100 gram staphylococcus lysozyme oral sprays.
A. divide earlier in addition staphylococcus lysozyme 2 is restrained, lysozyme 15 grams, sorbitol 7 grams, potassium phosphate 9 grams, sodium chloride 0.8 gram mixing adds bacitracin bacitracin2.5 again and restrains, Herba Menthae essence 0.1 gram and distilled water 64.1ml, mixing fill.This prescription is to staphylococcus aureus sterilizing rate 99.9%
B. earlier respectively with staphylococcus lysozyme 3 grams, lysozyme 10 restrains, sorbitol 7 grams, and potassium phosphate 10 grams, sodium chloride 1 gram mixing adds bacitracin bacitracin 3 grams again, and Fructus Citri Limoniae essence 0.1 restrains and distilled water 65.9ml the mixing fill.This prescription is to staphylococcus aureus sterilizing rate 99.5%
C. earlier respectively with staphylococcus lysozyme 1 gram, lysozyme 20 restrains, sorbitol 6 grams, and potassium phosphate 7 grams, sodium chloride 0.5 gram mixing adds bacitracin bacitracin2 gram again, and Fructus Mangifera Indicae essence 0.05 restrains and distilled water 63.45ml the mixing fill.This prescription is to staphylococcus aureus sterilizing rate 99.3%.
Claims (2)
1, a kind of composite lysostaphin enzyme spray for oral cavity is characterized in that this spray forms (percentage by weight) by following composition:
Main component: 1. staphylococcus lysozyme 1-3%
2. lysozyme 10-20%
Adjuvant: 3. sorbitol 6-7%
4. potassium phosphate 7-10%
5. sodium chloride 0.5～1%
6. essence 0.1%
7. bacitracin 2-3%
8. distilled water 60～70%
2, a kind of preparation method of a kind of composite lysostaphin enzyme spray for oral cavity as claimed in claim 1, it is characterized in that this method is in sterilizing room, with the 1-3% staphylococcus lysozyme, the 10-20% lysozyme, the 6-7% sorbitol, the 7-10% potassium phosphate, 0.5-1% sodium chloride adds in the clean glass or rustless steel container in proportion successively, stir gently, after fully mixing evenly, add the bacitracin of 2-3% again, 0.1% essence and 60-70% distilled water, abundant mixing, fill is put in storage in plastic bottle or metal bottle, and room temperature preservation gets final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00116396 CN1131068C (en) | 2000-06-08 | 2000-06-08 | Composite lysostaphin enzyme spray for oral cavity and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00116396 CN1131068C (en) | 2000-06-08 | 2000-06-08 | Composite lysostaphin enzyme spray for oral cavity and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1327854A CN1327854A (en) | 2001-12-26 |
| CN1131068C true CN1131068C (en) | 2003-12-17 |
Family
ID=4585800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00116396 Expired - Lifetime CN1131068C (en) | 2000-06-08 | 2000-06-08 | Composite lysostaphin enzyme spray for oral cavity and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1131068C (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100450546C (en) * | 2002-01-28 | 2009-01-14 | 上海高科生物工程有限公司 | Compound preparation for dissolving staphyloase and preparation method |
| CN102525856A (en) * | 2012-01-09 | 2012-07-04 | 江苏雪豹日化有限公司 | Biological compound enzyme oral spray and preparation method thereof |
| CN103705912B (en) * | 2013-12-20 | 2015-10-28 | 江苏雪豹日化有限公司 | A kind of composite lysozyme oral spray and preparation method thereof |
| CN103736084A (en) * | 2013-12-24 | 2014-04-23 | 童渝 | Composite lysozyme oral spray and preparation method thereof |
| CN104606672A (en) * | 2014-12-11 | 2015-05-13 | 杨陈 | Staphylococcus-dissolving composite enzyme sterilization spraying agent and preparation method thereof |
| CN104524558A (en) * | 2014-12-11 | 2015-04-22 | 杨陈 | Enzyme compounded preparation and preparation method thereof |
| CN104721812A (en) * | 2014-12-16 | 2015-06-24 | 杨陈 | Lysostaphin compound enzyme disinfectant and preparation method thereof |
| CN104524559A (en) * | 2014-12-16 | 2015-04-22 | 杨陈 | Lysostaphic complex enzyme oral cavity disinfectant and preparation method thereof |
| CN104996467A (en) * | 2015-08-12 | 2015-10-28 | 江苏绿科生物技术有限公司 | Complex lysostaphin disinfectant |
| CN105169378A (en) * | 2015-08-12 | 2015-12-23 | 江苏绿科生物技术有限公司 | Preparation method of complex lysostaphin disinfectant |
| CN106938046A (en) * | 2017-03-16 | 2017-07-11 | 韦毅 | A kind of antibacterial peptide complex enzyme oral spray |
| CN107029210A (en) * | 2017-04-22 | 2017-08-11 | 通化康元生物科技有限公司 | Wood frog's fallopian tube antibacterial peptide oral spray |
| CN107280997A (en) * | 2017-06-20 | 2017-10-24 | 江苏开源康达医疗器械有限公司 | A kind of composite lysozyme sterilization ora, disinfectant and preparation method thereof |
-
2000
- 2000-06-08 CN CN 00116396 patent/CN1131068C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1327854A (en) | 2001-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jhajharia et al. | Biofilm in endodontics: a review | |
| Krithikadatta et al. | Disinfection of dentinal tubules with 2% chlorhexidine, 2% metronidazole, bioactive glass when compared with calcium hydroxide as intracanal medicaments | |
| O'Reilly et al. | A history of oral sepsis as a cause of disease. | |
| CN1131068C (en) | Composite lysostaphin enzyme spray for oral cavity and its preparing process | |
| Goztas et al. | Antimicrobial effect of ozonated water, sodium hypochlorite and chlorhexidine gluconate in primary molar root canals | |
| Camacho-Alonso et al. | Effects of photodynamic therapy, 2% chlorhexidine, triantibiotic mixture, propolis and ozone on root canals experimentally infected with Enterococcus faecalis: an in vitro study | |
| KR20070092095A (en) | Disinfection compositions and methods for their preparation and use | |
| CN1367018A (en) | Compound preparation of staphylococcolysis enzyme and its preparation method and application | |
| Satti et al. | Indigenous irrigants as potent antimicrobials in endodontic treatment: An: in vitro: study | |
| CN102525841A (en) | Marine organism bacterium-removal oral care liquid | |
| CN1125592C (en) | Compound lysostaphin enzyme disinfectant | |
| CN1309304C (en) | Sterilizing gel, preparing method and application thereof | |
| CN1238054C (en) | Biotechnological formulation for suppressing and killing helicobacter pylori, its preparation and use | |
| Moukarab | Evaluation of antimicrobial activity of manually agitate (nano-chitosan and nano-propolis) against Enterococcus faecalis in comparison with sodium hypochlorite: an in-vitro study | |
| JP2006525981A (en) | Allicin | |
| Shurrab | Antimicrobial Efficiency of Some Antiseptic Products on Endodontic Micoflora Isolated from Gangrenous Pulp Tissue | |
| CN111700910A (en) | Cleaning disinfectant for preventing human from infecting animal germs | |
| CN1173690C (en) | Gargle with lysostaphin complex enzyme and its prepn | |
| Somayaji et al. | Comparison of antimicrobial efficacy of triphala, Withania somnifera and sodium hypochlorite against Enterococcus faecalis biofilm-An in vitro study | |
| CN1229104C (en) | Composition for preventing and curing gingivitis | |
| CN1788568A (en) | Quick-effective iodine disinfectant and production method thereof | |
| CN1132517C (en) | Compound lysostaphin enzyme disinfectant | |
| Sneha et al. | Bactericidal activity of ayurvedic formulation against cariogenic microorganisms | |
| CN1137979C (en) | Composite lysostaphin washings and preparing method | |
| CN102525856A (en) | Biological compound enzyme oral spray and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20031217 |
|
| CX01 | Expiry of patent term |